Table 1.
Patient characteristics MRS substudy. Decimal round method if not otherwise specified.
| Characteristics | All Patients (n = 19) | Group B (n = 8) |
|---|---|---|
| Group A (n = 11) | ||
| General | ||
| Age, median | 53 (range 38–64) | 42.5 (range 25–61) |
| Age, mean | 53 (SD = 7) | 41 (SD = 14) |
| Karnofsky index, mean rounded to nearest tenth (SD) | 90 (SD = 13) | 90 (SD = 6) |
| Histology | ||
| Glioblastoma, IDH wildtype, WHO IV (n) | 5 | 3 |
| Glioblastoma IDH-mutant, WHO IV (n) | 1 | 1 |
| Glioblastoma IDH-mutant, IDH unknown, WHO IV (n) | 4 | 1 |
| Anaplastic astrocytoma, IDH wildtype, WHO III (n) | 1 | 0 |
| Oligodendroglioma, IDH-mutant and 1p/19q co-deleted, WHO II (n) | 0 | 1 |
| Pleomorphic Xanthoastrocytoma, IDH wildtype (n) | 0 | 1 |
| Undifferentiated neuroepithelial tumor, NOS, WHO IV (n) | 0 | 1 |
| MGMT promotor methylation status | ||
| Not methylated | 46% (n = 5) | 63% (n = 5) |
| Methylated | 46% (n = 5) | 25% (n = 2) |
| Not known | 9% (n = 1) | 13% (n = 1) |
| Prior treatment | ||
| Radiation therapy up to 60 Gy | 100% (n = 11) | 100% (n = 8) |
| Concomitant TMZ | 100% (n = 11) | 88% (n = 7) |
| Median of adjuvant cycles of TMZ | 6 | 3 |
| Prior treatment with Bevacizumab | 18% (n = 2) | 13% (n = 1) |
| Resection prior to study treatment | 9% (n = 1) | 50% (n = 4) |
| Time interval first and second irradiation (months) | ||
| Median | 9 | 11 |
| Mean | 14 (SD = 9) | 17 (SD = 16) |